ParkinsonCanadaV1, Main, Merge, bibRecord, 003E15

Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958

Identifieur interne : 003E15 ( Main/Merge ); précédent : 003E14; suivant : 003E16

Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958

Auteurs : R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]

Source :

European journal of pharmacology [ 0014-2999 ] ; 1999.

RBID : Pascal:99-0436170

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Récepteur dopaminergique D1, Agoniste, Parkinson maladie, Dyskinésie, Corps strié, Système nerveux central, Encéphale, Putamen, Animal, Singe, Long terme, Voie souscutanée, Pompe osmotique, Forme libération lente, Dopamine, Catécholamine, Messager secondaire, SKF 82958.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- Agonist, Animal, Antiparkinson agent, Brain (vertebrata), Catecholamine, Central nervous system, Corpus striatum, D1 Dopamine receptor, Dopamine, Dyskinesia, Long term, Monkey, Osmotic pump, Parkinson disease, Putamen, Second messenger, Slow release form, Subcutaneous administration.

Abstract

The density of dopamine D₁ receptor antagonist sites was measured by autoradiography and dopamine D₁ receptor mRNA levels were measured by in situ hybridization in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed monkeys chronically treated with the dopamine D₁ receptor agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrobromide (SKF-82958) administered in intermittent or continuous mode for a month. Normal and MPTP-exposed but otherwise untreated animals were used for comparison. Intermittent treatment with SKF-82958 relieved parkinsonian features and induced dyskinesias whereas given continuously this drug induced behavioral tolerance without dyskinesias. On the one hand, MPTP treatment tended to increase dopamine D₁receptor density in the putamen whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant increase compared to control animals. On the other hand, dopamine D₁ receptor mRNA levels in the putamen appeared to decrease after MPTP lesion and agonist treatment as compared to dopamine D₁receptor density. In contrast, an apparent decrease in dopamine D₁ receptor density and mRNA levels was observed in the nucleus accumbens of untreated MPTP monkeys whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant decrease compared to control animals. Thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine D, receptors, respectively.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000D50
to stream PascalFrancis, to step Curation: 001173
to stream PascalFrancis, to step Checkpoint: 000C62

Links to Exploration step

Pascal:99-0436170

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine D<sub>1</sub>
 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958</title>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0436170</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0436170 INIST</idno>
<idno type="RBID">Pascal:99-0436170</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D50</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001173</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C62</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C62</idno>
<idno type="wicri:Area/Main/Merge">003E15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine D<sub>1</sub>
 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958</title>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Animal</term>
<term>Antiparkinson agent</term>
<term>Brain (vertebrata)</term>
<term>Catecholamine</term>
<term>Central nervous system</term>
<term>Corpus striatum</term>
<term>D1 Dopamine receptor</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Long term</term>
<term>Monkey</term>
<term>Osmotic pump</term>
<term>Parkinson disease</term>
<term>Putamen</term>
<term>Second messenger</term>
<term>Slow release form</term>
<term>Subcutaneous administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Récepteur dopaminergique D1</term>
<term>Agoniste</term>
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Corps strié</term>
<term>Système nerveux central</term>
<term>Encéphale</term>
<term>Putamen</term>
<term>Animal</term>
<term>Singe</term>
<term>Long terme</term>
<term>Voie souscutanée</term>
<term>Pompe osmotique</term>
<term>Forme libération lente</term>
<term>Dopamine</term>
<term>Catécholamine</term>
<term>Messager secondaire</term>
<term>SKF 82958</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The density of dopamine D<sub>1</sub>
 receptor antagonist sites was measured by autoradiography and dopamine D<sub>1</sub>
 receptor mRNA levels were measured by in situ hybridization in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed monkeys chronically treated with the dopamine D<sub>1</sub>
 receptor agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrobromide (SKF-82958) administered in intermittent or continuous mode for a month. Normal and MPTP-exposed but otherwise untreated animals were used for comparison. Intermittent treatment with SKF-82958 relieved parkinsonian features and induced dyskinesias whereas given continuously this drug induced behavioral tolerance without dyskinesias. On the one hand, MPTP treatment tended to increase dopamine D<sub>1</sub>
receptor density in the putamen whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant increase compared to control animals. On the other hand, dopamine D<sub>1</sub>
 receptor mRNA levels in the putamen appeared to decrease after MPTP lesion and agonist treatment as compared to dopamine D<sub>1</sub>
receptor density. In contrast, an apparent decrease in dopamine D<sub>1</sub>
 receptor density and mRNA levels was observed in the nucleus accumbens of untreated MPTP monkeys whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant decrease compared to control animals. Thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine D, receptors, respectively.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
</noRegion>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E15 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003E15 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:99-0436170
   |texte=   Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958

Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri